Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Study ID
- NCT07478848
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Diffuse Large B Cell Lymphoma Refractory
- Diffuse Large B Cell Lymphoma Relapsed
- Large B Cell Lymphoma
- Non Hodgkin Lymphoma (NHL)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Vancomycin 125mg — DRUGoral
- Radiation Therapy — RADIATIONRadiation Therapy
- CAR-T — BIOLOGICALstandard of care anti-CD19 CAR-T
Study Details
This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas
Key Dates
- First listed
- Mar 18, 2026
- Start date
- May 29, 2026
- Status verified
- Jun 2026
- Primary completion
- Jan 1, 2029
- Completion
- Jan 1, 2029
Study Design
- Enrollment
- 14 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: vancomycin, radiation therapy, and CAR-Tvancomycin 125 mg orally four times per day, followed by standard of care radiation and standard of care CD19 CAR T-cells
Primary Outcome Measure
Cytokine release syndrome [ Time Frame: date of CAR-T infusion to 28 days after infusion ]
Central Contacts
- Rachel Lundberg, PA-C215-615-5858
- Megan Jones, MPH
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Abramson Cancer Center, University of Pennsylvania | Philadelphia | Pennsylvania | 19104 |
Find similar trials in Philadelphia, PA
Related Studies
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesPHASE1 · Recruiting · Nurix Therapeutics, Inc. · Duarte, California
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyPHASE3 · Recruiting · Lyell Immunopharma, Inc. · Gilbert, Arizona
- CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesPHASE1/PHASE2 · Recruiting · Medical College of Wisconsin · Milwaukee, Wisconsin
- A Study of NX-1607 in Adults With Advanced MalignanciesPHASE1 · Recruiting · Nurix Therapeutics, Inc. · Los Angeles, California